HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS
LATEST UPDATES » Vol 25, No. 04, April 2021 – The Evolution of Medicine – Exploring the Contributions of Sony’s Technology       » Potential Target and Neural Circuitry for Psychiatric Conditions       » Study Provides Insight to Cause of Coral Necrotic Death       » Combination of X-Rays and AI for Quicker Diagnosis of COVID-19       » Clinical Study Achieves Goals in Diagnosing Rare Childhood Disorders       » Portable Device to Detect Plant Stress      
Vol 24, No. 05, May 2020   |   Issue PDF view/purchase
COLUMNS
CytoMed Therapeutics — Pioneer in Advancing Cellular Immunotherapy against Cancer
First incorporated in 2018, CytoMed Therapeutics is a start-up spin-off from the Agency for Science, Technology and Research (A*STAR). Its main focus is to leverage on their proprietary technologies to develop “off-the-shelf” immunotherapeutics for a wide range of cancers.

Since the first discovery by scientists to derive embryonic stem cells from mouse embryos in the 1980s, the potential of stem cells in scientific research and disease therapy has progressed in an unprecedented way. Following this discovery was the next breakthrough in stem cell research, notably by Shinya Yamanaka and his team in Kyoto, Japan. In 2006, he announced to the scientific world how he successfully reprogrammed adult cells back to pluripotency to become induced pluripotent stem cells. The ingredients behind this process were the use of four genes— Myc, Oct3/4, Sox2 and Klf4 — which code for transcription factors enabled this conversion.

Today, scientists have found ways through the foundations of the initial discovery of stem cells and the work of Shinya Yamanaka to leverage on the immense potential of the properties of stem cells for disease treatment.

CytoMed Therapeutics, a Singapore-based company is working on using stem cells to provide “off-the-shelf” immunotherapy against various cancers. The company started out in 2018 and is based off the research of A*STAR researchers since 2007. Its strong scientific base established the three main technology platforms that CytoMed Therapeutics offers.

CytoMed Therapeutics main technologies revolve around the following three platforms:

1. Donor blood cell-based platform

Isolation of mononuclear cells from a blood draw sample to create CAR-ϒδT cells. These cells have the potential for applicable for use by many patients for more affordable, “off-the-shelf” product. The creation of the CAR-ϒδT cells is through mRNA electroporation.

2. Induced pluripotent stem cell (iPSC)-based platform

Cytomed Therapeutics uses its iPSC generation technology for reprogramming of mononuclear cells in blood to produce blood cell-derived iPSCs. The proprietary protocol is then applied to these cells to develop ϒδT cells and natural killer (NK) cells.

3. Mesenchymal stem cell (MSC)-based platform

MSCs are sourced from the umbilical cord to be used for differentiation to other cells and cryopreserved until it is required. These cells, CytoMed believes to have the potential for development into an “off-the-shelf” product for cancer therapy.

One subsidiary of CytoMed Therapeutics, iPSCbank, provides services for banking of one’s peripheral blood mononuclear cells, induced pluripotent stem cells and mesenchymal stem cells for future use. Cell are isolated through a blood draw sample and with consent from the customer.

CytoMed Therapeutics is also actively seeking collaboration with medical institutions and doctors; as well as research opportunities with cancer research centres across Asia Pacific. On 26 February 2019, CytoMed Therapeutics together with Clinical Research Malaysia signed a memorandum of understanding to pursue advancements in development of medicines specifically for cell therapy and cancer research.

 

NEWS CRUNCH  
news Commemorating World Health Day with Viatris
news Entire industrial chain resources of advanced medical equipment are lining up at Medtec China 2021
news CPhI & P-MEC China gives a glimpse of the success returning pharma events will deliver in 2021
news Highlights from the E&L China 2020 Conference
SPOTLIGHT  

MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Contribute to APBN
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Deborah Seah
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   biotech_ad@wspc.com
Copyright© 2021 World Scientific Publishing Co Pte Ltd  •  Privacy Policy